Athenex announces initiation of Phase 1 clinical study of KX2-361 in China
Athenex announced that its partner, Guangzhou Xiangxue Pharmaceutical Co., Ltd., initiated a Phase I study in China of KX2-361 oral treating advanced malignant solid tumors. KX2-361, which is being developed for the treatment of glioblastoma multiforme, is the second compound derived from Athenex's Src kinase inhibition platform. It is a closely related structural analog of Athenex's tirbanibulin with a distinct ability to cross the blood brain barrier, making it a potential therapeutic candidate for treating brain cancers, including GBM, as well as brain metastases. Studies of KX2-361 oral in preclinical mouse GBM tumor models resulted in complete tumor eradication as well as extended survival compared to the current standard of care, temozolomide. The Phase I clinical study in China is a single-center, open-label dose escalation trial that will enroll 36-72 patients with advanced malignant solid tumors who have no standard treatment or standard treatment failed.